SignorelliSSAnzaldiMLibraM, et al.Plasma levels of inflammatory biomarkers in peripheral arterial disease: results of a cohort study. Angiology. 2016;67(9):870–874.
2.
BrogneauxCSpryngerMMagnéeM, et al.2011ESC guidelines on the diagnosis and treatment of peripheral artery diseases. Rev Med Liege. 2012;67(11):560–565.
3.
HennionDRSianoKA. Diagnosis and treatment of peripheral arterial disease. Am Fam Physician. 2013;88(5):306–310.
4.
KucukseymenSYukselIOArslanS. C-reactive protein is the origin for novel biomarkers. Angiology. 2016. doi:10.1177/0003319717690305.
5.
GalkinaELeyK. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165–197.
6.
BrevettiGGiuglianoGBrevettiL, et al.Inflammation in peripheral artery disease. Circulation. 2010;122(18):1862–1875.
7.
SignorelliSSFioreVMalaponteG. Inflammation and peripheral arterial disease: the value of circulating biomarkers. Int J Mol Med. 2014;33(4):777–783.
LiJLiJJLiQ, et al.A rational connection of inflammation with peripheral arterial disease. Med Hypotheses. 2007;69(6):1190–1195.
10.
CannonCPBraunwaldEMcCabeCH, et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504.
11.
RidkerPMDanielsonEFonsecaFA, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
12.
CharoIFTaubR. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov. 2011;10(5):365–376.
13.
BaileyJMButlerJ. Anti-inflammatory drugs in experimental atherosclerosis. Part 6. Combination therapy with steroid and non-steroid agents. Atherosclerosis. 1985;54(2):205–212.
14.
EtzioniA. Adhesion molecules—their role in health and disease. Pediatr Res. 1996;39(2):191–198.
